Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Kinetics of measles antibody by hemagglutination inhibition assay in children in south-west and north-central Nigeria.

Onoja AB, Adeniji AJ.

Int J Infect Dis. 2013 Jul;17(7):e552-5. doi: 10.1016/j.ijid.2013.02.001. Epub 2013 Mar 17.

2.

Determination of measles hemagglutination inhibiting antibody levels among school children in Ibadan, Nigeria.

Ogundiji OT, Okonko IO, Adu FD.

J Immunoassay Immunochem. 2013;34(2):208-17. doi: 10.1080/15321819.2012.699496.

PMID:
23537304
3.
4.
5.

[The development and duration of immunity in children vaccinated against measles with the Edmonston-Zagreb vaccine].

Borcić B, Smerdel S, Abu Eldan J, Kolić J, Ferdebar M, Kordić D, Mohacek N.

Lijec Vjesn. 1989 Apr-May;111(4-5):131-4. Croatian.

PMID:
2770398
6.

Measles revaccination. Persistence and degree of antibody titer by type of immune response.

Deseda-Tous J, Cherry JD, Spencer MJ, Welliver RC, Boyer KM, Dudley JP, Zahradnik JM, Krause PJ, Walbergh EW.

Am J Dis Child. 1978 Mar;132(3):287-90.

PMID:
629246
8.

In vitro effect of haemagglutination inhibition antibodies on measles virus replication.

Odama LE, Eghafona NO, Emejuaiwe SO.

Microbios. 1985;43(174-175):181-3.

PMID:
4094569
9.

Persistence of vaccine-induced antibody to measles 26-33 years after vaccination.

Dine MS, Hutchins SS, Thomas A, Williams I, Bellini WJ, Redd SC.

J Infect Dis. 2004 May 1;189 Suppl 1:S123-30.

PMID:
15106101
10.

Current chemotherapy protocols for childhood acute lymphoblastic leukemia induce loss of humoral immunity to viral vaccination antigens.

Nilsson A, De Milito A, Engström P, Nordin M, Narita M, Grillner L, Chiodi F, Björk O.

Pediatrics. 2002 Jun;109(6):e91.

PMID:
12042585
11.

Seroepidemiological study on prevalence of measles antibodies in Urawa City.

Tsuji A, Tanioku Y, Nakayama T.

Keio J Med. 1998 Dec;47(4):209-11.

12.

Poor serologic responses five to seven years after immunization with high and standard titer measles vaccines.

Whittle H, Aaby P, Samb B, Cissé B, Kanteh F, Soumaré M, Jensen H, Bennett J, Simondon F.

Pediatr Infect Dis J. 1999 Jan;18(1):53-7.

PMID:
9951981
13.
15.

Measles virus antibody responses in children randomly assigned to receive standard-titer edmonston-zagreb measles vaccine at 4.5 and 9 months of age, 9 months of age, or 9 and 18 months of age.

Martins C, Garly ML, Bale C, Rodrigues A, Njie-Jobe J, Benn CS, Whittle H, Aaby P.

J Infect Dis. 2014 Sep 1;210(5):693-700. doi: 10.1093/infdis/jiu117. Epub 2014 Mar 31.

PMID:
24688075
16.

Measles vaccine potency and sero-conversion rates among infants receiving measles immunization in Ilorin, Kwara State, Nigeria.

Fowotade A, Okonko IO, Nwabuisi C, Bakare RA, Fadeyi A, Adu FD.

J Immunoassay Immunochem. 2015;36(2):195-209. doi: 10.1080/15321819.2014.920713.

PMID:
24825255
17.

Haemagglutination inhibition antibody levels one year after natural measles infection and vaccination.

Eghafona NO, Ahmad AA, Ezeokoli CD, Emejuaiwe SO.

Microbios. 1991;67(274):33-6.

PMID:
1758308
18.

Effect of subclinical infection on maintaining immunity against measles in vaccinated children in West Africa.

Whittle HC, Aaby P, Samb B, Jensen H, Bennett J, Simondon F.

Lancet. 1999 Jan 9;353(9147):98-102.

PMID:
10023894
19.

Decay of maternally derived measles antibody in a highly vaccinated population in southern Israel.

Dagan R, Slater PE, Duvdevani P, Golubev N, Mendelson E.

Pediatr Infect Dis J. 1995 Nov;14(11):965-9.

PMID:
8584363

Supplemental Content

Support Center